

Narendranath Epperla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6327310/publications.pdf>

Version: 2024-02-01

163
papers

1,668
citations

304602

22
h-index

414303

32
g-index

167
all docs

167
docs citations

167
times ranked

2618
citing authors

#	ARTICLE	IF	CITATIONS
1	Râ€œ<sc>CHOP </sc><i>versus</i> doseâ€œadjusted Râ€œ<sc>EPOCH</sc> in frontline management of primary mediastinal Bâ€œcell lymphoma: a multiâ€œcentre analysis. British Journal of Haematology, 2018, 180, 534-544.	1.2	70
2	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood, 2021, 137, 374-386.	0.6	59
3	Incidence, Risk Factors for and Outcomes of Transplantâ€œAssociated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	1.2	58
4	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphomaâ€œa â€œreal worldâ€œstudy. Hematological Oncology, 2017, 35, 528-535.	0.8	56
5	Diffuse large Bâ€œcell lymphoma with primary treatment failure: Ultraâ€œhigh risk features and benchmarking for experimental therapies. American Journal of Hematology, 2017, 92, 161-170.	2.0	56
6	Medical Management of Pump-Related Thrombosis in Patients with Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. ASAIO Journal, 2017, 63, 373-385.	0.9	49
7	Incidence and survival trends in mantle cell lymphoma. British Journal of Haematology, 2018, 181, 703-706.	1.2	46
8	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncology, 2021, 7, 993.	3.4	44
9	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer, 2018, 124, 2306-2315.	2.0	40
10	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncology, 2020, 6, 1011.	3.4	39
11	Burkitt Lymphoma International Prognostic Index. Journal of Clinical Oncology, 2021, 39, 1129-1138.	0.8	37
12	SjÃ¶grenâ€œs syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) - a case report and review of literature. BMC Neurology, 2014, 14, 200.	0.8	36
13	Emerging therapies in mantle cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 79.	6.9	33
14	Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Clinical Medicine and Research, 2015, 13, 32-35.	0.4	29
15	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Journal of Hematology and Oncology, 2019, 12, 6.	6.9	29
16	Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. SpringerPlus, 2015, 4, 455.	1.2	28
17	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 277-284.	0.6	27
18	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Advances, 2018, 2, 933-940.	2.5	27

#	ARTICLE	IF	CITATIONS
19	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	3.2	26
20	Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. <i>Transfusion</i> , 2017, 57, 2775-2781.	0.8	25
21	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. <i>Cancer Management and Research</i> , 2018, Volume 10, 615-624.	0.9	24
22	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
23	<scp>Câ€MYC</scp>â€“positive relapsed and refractory, diffuse large <scp>B</scp>â€cell lymphoma: Impact of additional â€œhitsâ€and outcomes with subsequent therapy. <i>Cancer</i> , 2017, 123, 4411-4418.	2.0	23
24	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	0.6	23
25	Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. <i>American Journal of Hematology</i> , 2016, 91, E313-4.	2.0	22
26	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	2.5	21
27	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 58-66.	0.6	21
28	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	1.7	21
29	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
30	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20
31	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020, 4, 47-54.	2.5	20
32	Relative Survival of Patients with Nodal Marginal Zone Lymphoma in the United States: A Population-Based Analysis. <i>Blood</i> , 2020, 136, 5-6.	0.6	18
33	Resistance mechanism for ibrutinib in marginal zone lymphoma. <i>Blood Advances</i> , 2019, 3, 500-502.	2.5	17
34	Outcomes of rituximabâ€BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17
35	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive Bâ€cell lymphomas in first remission in the rituximab era: A systematic review and metaâ€analysis. <i>Cancer</i> , 2019, 125, 4417-4425.	2.0	16
36	Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013203056-bcr2013203056.	0.2	15

#	ARTICLE	IF	CITATIONS
37	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15
38	Recent survival trends in diffuse large B-cell lymphoma—“Have we made any progress beyond rituximab?”. <i>Cancer Medicine</i> , 2020, 9, 5519-5525.	1.3	15
39	Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. <i>American Journal of Hematology</i> , 2016, 91, 644-646.	2.0	14
40	A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene. <i>Blood</i> , 2019, 133, 1888-1898.	0.6	14
41	Apical Hypertrophic Cardiomyopathy Presenting as Recurrent Unexplained Syncope. <i>Clinical Medicine and Research</i> , 2012, 10, 26-31.	0.4	13
42	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2862-2870.	0.6	13
43	Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 904.	1.8	13
44	Integration of Metabolomics and Gene Expression Profiling Elucidates IL41 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. <i>Cancers</i> , 2021, 13, 2146.	1.7	13
45	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. <i>Journal of Hematology and Oncology</i> , 2021, 14, 104.	6.9	13
46	Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. <i>Bone Marrow Transplantation</i> , 2016, 51, 1602-1604.	1.3	12
47	A rash diagnosis: Gemcitabine-associated pseudocellulitis. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 157-160.	0.5	12
48	Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleuce (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021, 138, 93-93.	0.6	12
49	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
50	Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1797-1805.	1.0	11
51	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
52	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. <i>Blood</i> , 2018, 132, 2305-2305.	0.6	11
53	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 237-238.	0.6	10
54	Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. <i>American Journal of Hematology</i> , 2018, 93, 238-245.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	0.6	10
56	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9
57	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 95-102.	0.2	9
58	Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). <i>American Journal of Hematology</i> , 2021, 96, E123-E126.	2.0	9
59	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	0.6	9
60	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9
61	Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – a case report. <i>Diagnostic Pathology</i> , 2013, 8, 192.	0.9	8
62	Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?. <i>Bone Marrow Transplantation</i> , 2015, 50, 1393-1404.	1.3	8
63	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 408-414.	0.2	8
64	ADAMTS13 Deficiency and Thrombotic Thrombocytopenic Purpura Associated with Trimethoprim-Sulfamethoxazole. <i>Clinical Medicine and Research</i> , 2013, 11, 86-90.	0.4	7
65	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 672-678.	0.2	7
66	Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2016, 91, 1161-1164.	2.0	7
67	Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasia. <i>Transfusion</i> , 2016, 56, 1801-1806.	0.8	7
68	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	2.0	7
69	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	0.6	7
70	Feasibility of High-dose Methotrexate Administered on Day 1 of (R)CHOP in aggressive non-Hodgkin Lymphomas. <i>Blood Advances</i> , 2021, , .	2.5	7
71	Non-Cardiogenic Pulmonary Edema Complicating Electroconvulsive Therapy: Short Review of the Pathophysiology and Diagnostic Approach. <i>Clinical Medicine and Research</i> , 2012, 10, 131-136.	0.4	6
72	Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014206214-bcr2014206214.	0.2	6

#	ARTICLE	IF	CITATIONS
73	Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. <i>Clinical Medicine and Research</i> , 2015, 13, 85-88.	0.4	6
74	Think outside the box : Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 175, 758-758.	1.2	6
75	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.2	6
76	Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States. <i>American Journal of Hematology</i> , 2021, 96, 816-822.	2.0	6
77	Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015210828.	0.2	6
78	Brain Abscesses Complicating Acute Pneumococcal Meningitis During Etanercept Therapy. <i>Clinical Medicine and Research</i> , 2012, 10, 230-235.	0.4	5
79	An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. <i>Skeletal Radiology</i> , 2014, 43, 1313-1318.	1.2	5
80	Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. <i>Bone Marrow Transplantation</i> , 2017, 52, 147-150.	1.3	5
81	Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?. <i>Annals of Hematology</i> , 2018, 97, 1727-1729.	0.8	5
82	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 983-988.	2.0	5
83	Outcomes after stereotactic radiosurgery for CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 465-476.	1.4	5
84	Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 47.	1.2	5
85	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021, 39, 473-482.	0.8	5
86	Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. <i>Cancer Medicine</i> , 2021, 10, 7330-7338.	1.3	5
87	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	1.2	5
88	A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 19-24.	1.2	5
89	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	0.6	5
90	Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 247-253.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Sweet's Syndrome: One Disease, Multiple Faces. <i>Clinical Medicine and Research</i> , 2011, 9, 134-136.	0.4	4
92	Radiographic findings in Waldenström's macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): A case report. <i>Skeletal Radiology</i> , 2014, 43, 381-385.	1.2	4
93	MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). <i>Hematological Oncology</i> , 2019, 37, 405-407.	0.8	4
94	How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. <i>Blood</i> , 2021, 138, 520-530.	0.6	4
95	Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. <i>Blood</i> , 2020, 136, 2-3.	0.6	4
96	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021, 138, 455-455.	0.6	4
97	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
98	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	3.2	3
99	What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? â€” is there a one to use or avoid. <i>British Journal of Haematology</i> , 2020, 190, 490-492.	1.2	3
100	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
101	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	0.6	3
102	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	0.6	3
103	Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. <i>World Journal of Transplantation</i> , 2015, 5, 81.	0.6	3
104	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. <i>Bone Marrow Transplantation</i> , 2019, 54, 913-916.	1.3	2
105	Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. <i>Cureus</i> , 2017, 9, e1262.	0.2	2
106	Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial. <i>Blood</i> , 2019, 134, 2853-2853.	0.6	2
107	Post-relapse survival in Waldenström macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	0.8	2
108	A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 29-29.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	1.3	2
110	An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. <i>BMC Hematology</i> , 2015, 15, 7.	2.6	1
111	Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S265-S266.	2.0	1
112	Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndromes. , 2018, , 1984-2000.		1
113	NCMP-12. RAPIDLY PROGRESSIVE NEUROPATHIES AS THE SOLE PRESENTATION OF NEUROLYMPHOMATOSIS. <i>Neuro-Oncology</i> , 2020, 22, ii125-ii125.	0.6	1
114	Recent Survival Trends in Diffuse Large B-Cell Lymphoma (DLBCL)-Did We Make Any Progress Beyond Rituximab?. <i>Blood</i> , 2018, 132, 4828-4828.	0.6	1
115	Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4185-4185.	0.6	1
116	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	0.6	1
117	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	0.6	1
118	Outcomes of Grade 3A Follicular Lymphoma: Best Treated As Aggressive or Indolent Lymphoma?. <i>Blood</i> , 2016, 128, 5328-5328.	0.6	1
119	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. <i>Blood</i> , 2018, 132, 4143-4143.	0.6	1
120	Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4082-4082.	0.6	1
121	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	0.6	1
122	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
123	Silo Filler's Disease: A Rare Cause of Acute Respiratory Distress Syndrome (ARDS). <i>Chest</i> , 2013, 144, 246A.	0.4	0
124	Unprovoked Deep Venous Thrombosis in Young Adult Associated with Membranous Obstruction of Inferior Vena Cava. <i>Chest</i> , 2013, 144, 976A.	0.4	0
125	1174. <i>Critical Care Medicine</i> , 2013, 41, A298-A299.	0.4	0
126	Chemotherapy: Response and Survival Data #99. <i>Journal of Palliative Medicine</i> , 2016, 19, 1011-1011.	0.6	0

#	ARTICLE	IF	CITATIONS
127	An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer, 2016, 47, 206-209.	0.6	0
128	Post-Relapse Survival in Lymphoma Patients (Pts) after Experiencing Therapy Failure Following an Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biology of Blood and Marrow Transplantation, 2017, 23, S48.	2.0	0
129	Post-Relapse Survival in Diffuse Large B-Cell Lymphoma (DLBCL) Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation (auto-HCT). Biology of Blood and Marrow Transplantation, 2019, 25, S22.	2.0	0
130	Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S23-S24.	2.0	0
131	PHASE I DOSE-ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH-RISK NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. Hematological Oncology, 2019, 37, 528-529.	0.8	0
132	OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. Hematological Oncology, 2019, 37, 408-410.	0.8	0
133	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). Blood, 2015, 126, 4360-4360.	0.6	0
134	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). Blood, 2015, 126, 3169-3169.	0.6	0
135	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Blood, 2015, 126, 2711-2711.	0.6	0
136	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. Blood, 2016, 128, 513-513.	0.6	0
137	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. Blood, 2016, 128, 103-103.	0.6	0
138	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. Journal of Clinical Oncology, 2017, 35, 7541-7541.	0.8	0
139	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 4153-4153.	0.6	0
140	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. Blood, 2018, 132, 2918-2918.	0.6	0
141	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2018, 132, 969-969.	0.6	0
142	Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States. Blood, 2018, 132, 4833-4833.	0.6	0
143	HSR19-086: Healthcare Costs and Resource Utilization Associated With Adverse Events Among Hairy Cell Leukemia Patients Treated With Purine Nucleoside Analogs. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, HSR19-086.	2.3	0
144	Abstract 481: Distinct and overlapping patterns of B-cell growth pathway mutations in CD5-negative B-cell lymphoproliferative disorders. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	0.6	0
146	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019, 134, 1554-1554.	0.6	0
147	Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20064-e20064.	0.8	0
148	Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8043-8043.	0.8	0
149	Hepatosplenic T-Cell Lymphoma. , 2020, , .		0
150	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021, 138, 1451-1451.	0.6	0
151	Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study. <i>Blood</i> , 2021, 138, 1425-1425.	0.6	0
152	Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
153	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020, 136, 24-26.	0.6	0
154	Racial and Ethnic Disparities in the Survival of Patients with Indolent Non-Hodgkin Lymphoma in the United States: A Population-Based Analysis. <i>Blood</i> , 2020, 136, 3-3.	0.6	0
155	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020, 136, 4-6.	0.6	0
156	Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. <i>Blood</i> , 2020, 136, 9-9.	0.6	0
157	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020, 136, 46-49.	0.6	0
158	Impact of Primary Site and Era of Diagnosis on Mortality in Patients with Extranodal Marginal Zone Lymphoma in the United States: A Population-Based Study. <i>Blood</i> , 2020, 136, 44-44.	0.6	0
159	Editorial: Rising Stars in Hematologic Malignancies 2021. <i>Frontiers in Oncology</i> , 2022, 12, 858564.	1.3	0
160	Racial differences in the survival of mantle cell lymphoma patients in the United States. <i>Hematological Oncology</i> , 2022, 40, 479-481.	0.8	0
161	Long-Term Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene CiloleuceL (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Transplantation and Cellular Therapy</i> , 2022, 28, S64-S65.	0.6	0
162	Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	1.1	0

#	ARTICLE	IF	CITATIONS
163	Abstract 481: Distinct and overlapping patterns of B-cell growth pathway mutations in CD5-negative B-cell lymphoproliferative disorders. , 2019, , .		0